NeuroNEXT Network

Standard Operating Procedure (SOP)

Generation and Validation of Analysis Data Sets

Version 3.0

SOP NN BIO 904

Signature and Date: DocuSigned by Christopher Coffey Christopher Coffey | I approve this document 17-Feb-2023 | 3:52:28 PM PST C68AC8DD80334CF982AED1200765F147 17-Feb-2023
Name and Title: Christopher S. Coffey, PhD (DCC Principal Investigator)
Signature and Date: DocuSigned by Merit Cudkowicz Merit Cudkowicz | I approve this document 17-Feb-2023 | 8:26:07 AM EST 9F8FE4180E504C6AB0A67B835E80C644 17-Feb-2023
Name and Title: Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)
Signature and Date: DocuSigned by Marianne Chase Marianne Chase | I approve this document 17-Feb-2023 | 1:30:54 PM EST 58FE690F6BCA4F2390E3DA15BCE3F578 17-Feb-2023
Name and Title: Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)

Signature and Date:

DocuSigned by DIXIE ECKLUND

I approve this document
17-Feb-2023 | 4:13:06 PM PST

7006AF622EFC40B6A067A08EC02591B6

17-Feb-2023

Name and Title: Dixie J. Ecklund, RN MSN MBA (DCC Director of Operations)

Signature and Date:

DocuSigned by Stacey Grabert

I approve this document
22-Feb-2023 | 11:11:27 AM EST

60CC52B0747A44E6B2208D8D880698C0

22-Feb-2023

Name and Title: Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

Signature and Date:

DocuSigned by Joan Ohayon

I approve this document
21-Feb-2023 | 6:39:58 AM PST

72C6AAFD8CC4485582ACA0700072901A

21-Feb-2023

Name and Title: Joan Ohayon, RN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

NN BIO 904

NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR GENERATION AND VALIDATION OF ANALYSIS DATA SETS

1. POLICY

This SOP describes NeuroNEXT Data Coordinating Center (DCC) procedures for creating and validating analysis data sets for:

- critical study analyses (analyses of the primary and secondary endpoints as described in the Statistical Analysis Plan [SAP]; interim analyses; and analyses for the final study report and primary manuscript; and
- analyses that are requested by study investigators or other authorized researchers and approved by the Sponsor and/or CTSDMC Leadership (e.g. for abstracts, presentations, or secondary analyses after the conclusion of the study).

Before data sets are created, all DCC databases are carefully developed, and the SOPs related to database development and validation (e.g., NN CS 702, NN CS 703, NN DM 1004), data collection and management (e.g., NN DM 1001, NN DM 1005), and routine monitoring visits (NN SS 403) are followed. The procedures described in these SOPs help to ensure that all data stored in DCC electronic databases are complete, and that all targeted data have been validated against source documents at the Clinical Study Sites (CSS).

Before the data sets are created, a written Statistical Analysis Plan (SAP) is developed that includes plans for final analyses as well as an *a priori* defined plan for interim analyses (see SOP NN BIO 902). Study endpoints that will be analyzed in the final and interim analyses are defined in the SAP. Analysis data sets are created so that the endpoints may be determined and analyzed according to the parameters defined in the SAP.

The SAS® statistical package is the primary tool used for analyses conducted at the DCC, and all analysis data sets are initially created in the SAS® format. If specific analysis methods require the use of another statistical format, the SAS® files are exported to that format.

2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). The policies and procedures described in this SOP apply to the NeuroNEXT Clinical Coordinating Center (CCC) and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, External Biostatisticians (if applicable), or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

3. ROLES AND RESPONSIBILITIES

DCC Biostatisticians are responsible for adhering to the procedures outlined in this SOP, and for ensuring that the procedures are followed by other DCC staff members who may participate in biostatistics projects.

The Independent Biostatisticians are responsible for generating specifications for analysis data sets (in consultation with the DCC PI, and the PPI as necessary), for creating and validating the SAS® data set, and for converting the SAS® data set to another format (if required for the analysis).

4. APPLICABLE REGULATIONSAND GUIDELINES

ICH E3	Structure and Content of Clinical Study Reports
ICH E6, 4.5	Compliance with Protocol
ICH E6, 4.9	Records and Reports
ICH E6, 5.1	Quality Assurance and Quality Control
ICH E6, 5.5	Trial Management, Data Handling and Record Keeping

ICH E8	General Considerations for Clinical Trials (December 1997)
ICH E9	Statistical Principles for Clinical Trials (September 1998)

5. REFERENCES TO OTHER APPLICABLE SOPS

NN CS 702	Application Development and Validation
NN CS 703	IT Environments
NN BIO 905	Validating Statistical Programs and Deliverables
NN DM 1001	Clinical Data Management
NN DM 1004	Specifications Development, Testing Plans, and Validation Documentation
NN DM 1005	Data Collection and Data Handling

6. ATTACHMENTS AND REFERENCES

NN BIO 904 - A	Document History

7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

CCC	Clinical Coordinating Center at Massachusetts General Hospital
DCC	Data Coordinating Center at The University of Iowa
DM	Data Management
DM Lead	Leader of the Data Management team at the DCC
External Biostatistician	A Biostatistician who is not a member of the DCC Biostatistics Team. An External Biostatistician may act as a Study Biostatistician for a study.
IT	Information Technology
IT Lead	Leader of the Information Technology team at the DCC
Independent Biostatisticians	Unblinded DCC Biostatisticians for a study. Typically, at least two Independent Biostatisticians will be assigned to each study.
PPI	Protocol Principal Investigator
QA	Quality Assurance
QA Officer	Quality Assurance officer for a study
SAP	Statistical Analysis Plan
Study Biostatistician	Blinded Biostatistician for a study.

8. SPECIFIC PROCEDURES

A. Generating Specifications for Analysis Data Sets

#	*Who*	*Task*	*Attachment/ Reference*	*Related SOP*
1.	DCC PI, DCC Independent Biostatisticians, and Study Biostatistician	For critical study analyses, thoroughly review the SAP and other relevant documents, and discuss the analysis with the PPI.		
2.	DCC Independent Biostatisticians	For critical study analyses designated in the SAP, obtain an in-depth understanding of study design, endpoint definitions, and the relevant statistical methods.		
3.	DCC Independent Biostatisticians	Consult with the PPI to resolve questions or to clarify ambiguities before generating analysis data sets.		
4.	DCC Independent Biostatisticians	Understand the structure of study database so that any necessary data manipulations may be performed.		
5.	DCC Independent Biostatisticians	Develop specifications for all derived variables that will be used in the analyses.		
6.	DCC Independent Biostatisticians	If an analysis will be based on locked data, coordinate with all NeuroNEXT DCC and CCC staff to ensure that the electronic study database is complete and ready to be locked before a data lock is performed.		

B. Creating Analysis Data Sets

#	*Who*	*Task*	*Attachment/ Reference*	*Related SOP*
1.	DCC IT Lead or designee	Perform data lock, if applicable, using agreed-upon specifications.		
2.	DCC Independent Biostatisticians	If a data lock is not conducted, create a frozen snapshot of the source data to be used in generating the analysis data set, and store the frozen source data in the appropriate location.		
3.	DCC Independent Biostatisticians	Perform necessary data manipulations, such as data table merges.		
4.	DCC Independent Biostatisticians	Create derived variables based on specifications.		

#	Who	Task	Attachment/ Reference	Related SOP
5.	DCC Independent Biostatisticians	Validate the derived variables: • Develop test code to create derived variables. • For critical study analyses, assign a second Biostatistician to independently code and create derived variables. • Compare values for derived variables and identify all values where there is disagreement. • Resolve cases where there is disagreement.		NN BIO 905

C. Validating Analysis Data Sets

#	Who	Task	Attachment/ Reference	Related SOP
1.	DCC Independent Biostatisticians	Validate the analysis data set: • Ensure that the appropriate observations are included in each table • Ensure that the appropriate variables are included in each table. • Ensure that treatment assignments are accurate. • Examine each variable in a data table to ensure that there are no unexpected missing values • Examine each variable to identify possible outliers.		
2.	DCC Independent Biostatisticians	Work with DCC IT and DCC Coordinators to determine if unusual values are real or should be corrected.		

D. Converting SAS® Data Sets to other Formats

#	Who	Task	Attachment/ Reference	Related SOP
1.	DCC Independent Biostatisticians	If required for the analysis, convert SAS® data sets to the desired format.		

#	*Who*	*Task*	*Attachment/ Reference*	*Related SOP*
2.	DCC Independent Biostatisticians	Perform QC checks to verify the integrity of the converted file and to ensure that values have been imported accurately and completely: • Spot-check the converted data set against the original data set. • Tabulate simple descriptive statistics • Compare the results in the two environments • Maintain documentation of the comparison.		

DocuSign

Certificate Of Completion

Envelope Id: 7B1F17AE619D4980BF82CEE1263977EE
Status: Completed
Subject: Complete with DocuSign: NN BIO 904 Generation and Validation of Analysis Data Sets v3.0.docx
Source Envelope:
Document Pages: 7
Signatures: 6
Envelope Originator:
Certificate Pages: 6
Initials: 0
Tania Leeder
AutoNav: Enabled
TLEEDER@PARTNERS.ORG
EnvelopeId Stamping: Disabled
IP Address: 73.123.188.5
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original
2/17/2023 8:19:43 AM
Holder: Tania Leeder
TLEEDER@PARTNERS.ORG
Location: DocuSign

Signer Events	Signature	Timestamp
Christopher Coffey christopher-coffey@uiowa.edu Security Level: Email, Account Authentication (Required), Login with SSO	 Signature Adoption: Pre-selected Style Signature ID: C68AC8DD-8033-4CF9-82AE-D1200765F147 Using IP Address: 128.255.113.139 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:22:56 AM Viewed: 2/17/2023 6:52:19 PM Signed: 2/17/2023 6:52:30 PM
Electronic Record and Signature Disclosure: Accepted: 2/17/2023 6:52:19 PM ID: f19d9963-9ee0-40fa-bd20-1bc22371a04f		
DIXIE ECKLUND dixie-ecklund@uiowa.edu Security Level: Email, Account Authentication (Required), Login with SSO	 Signature Adoption: Drawn on Device Signature ID: 7006AF62-2EFC-40B6-A067-A08EC02591B6 Using IP Address: 128.255.112.230 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:22:57 AM Viewed: 2/17/2023 7:12:27 PM Signed: 2/17/2023 7:13:08 PM
Electronic Record and Signature Disclosure: Accepted: 2/17/2023 7:12:27 PM ID: 1aff6582-d79c-495f-8f38-d9a69e338472		

Signer Events	Signature	Timestamp
Joan Ohayon ohayonj@ninds.nih.gov Security Level: Email, Account Authentication (Required), Logged in **Electronic Record and Signature Disclosure:** Accepted: 2/13/2023 2:03:22 PM ID: 385a0a53-0f0c-4395-88f6-d5700c36e050	 Signature Adoption: Pre-selected Style Signature ID: 72C6AAFD-8CC4-4855-82AC-A0700072901A Using IP Address: 156.40.137.188 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:22:58 AM Resent: 2/21/2023 8:25:36 AM Viewed: 2/21/2023 9:39:44 AM Signed: 2/21/2023 9:40:02 AM
Marianne Chase MCHASE@mgh.harvard.edu Sr Director, Clinical Trial Operations Insight OBO The Massachusetts General Hospital Security Level: Email, Account Authentication (Required), Logged in **Electronic Record and Signature Disclosure:** Not Offered via DocuSign	 Signature Adoption: Pre-selected Style Signature ID: 58FE690F-6BCA-4F23-90E3-DA15BCE3F578 Using IP Address: 73.114.253.109 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:22:57 AM Viewed: 2/17/2023 1:30:31 PM Signed: 2/17/2023 1:30:57 PM
Merit Cudkowicz cudkowicz.merit@mgh.harvard.edu Chief of Neurology Security Level: Email, Account Authentication (Required), Logged in **Electronic Record and Signature Disclosure:** Accepted: 2/17/2023 8:25:57 AM ID: 9aa4507a-953f-41bf-a025-d2040fbc5bc0	 Signature Adoption: Pre-selected Style Signature ID: 9F8FE418-0E50-4C6A-B0A6-7B835E80C644 Using IP Address: 68.239.56.73 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:22:56 AM Viewed: 2/17/2023 8:25:57 AM Signed: 2/17/2023 8:26:10 AM

Signer Events	Signature	Timestamp
Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	 Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:22:58 AM Resent: 2/21/2023 8:25:37 AM Viewed: 2/22/2023 11:11:13 AM Signed: 2/22/2023 11:11:30 AM
Electronic Record and Signature Disclosure: Accepted: 7/20/2020 8:50:14 AM ID: 5ebadf74-e399-40fd-be82-9c7ca902061b		

In Person Signer Events	Signature	Timestamp

Editor Delivery Events	Status	Timestamp

Agent Delivery Events	Status	Timestamp

Intermediary Delivery Events	Status	Timestamp

Certified Delivery Events	Status	Timestamp

Carbon Copy Events	Status	Timestamp

Witness Events	Signature	Timestamp

Notary Events	Signature	Timestamp

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/17/2023 8:22:59 AM
Certified Delivered	Security Checked	2/22/2023 11:11:13 AM
Signing Complete	Security Checked	2/22/2023 11:11:30 AM
Completed	Security Checked	2/22/2023 11:11:30 AM

Payment Events	Status	Timestamps

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a $0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Insight OBO The Massachusetts General Hospital:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:
To contact us by email send messages to: jhenrique@mgh.harvard.edu

To advise Insight OBO The Massachusetts General Hospital of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at jhenrique@mgh.harvard.edu and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Insight OBO The Massachusetts General Hospital

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Insight OBO The Massachusetts General Hospital

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.